Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Biomaterials. 2014 Jul 12;35(30):8635–8648. doi: 10.1016/j.biomaterials.2014.06.040

Figure 4. Effect of PLGA-CUR NPs in tumor growth and cytocompatibility in xenograft male nude mouse model.

Figure 4

(A) PLGA-CUR NPs significantly reduce the tumor growth in C4-2 xenograft mice. Following tumor development, the mice were treated intratumorally one time with 25 μg CUR or PLGA-CUR NPs or respective controls (DMSO or PLGA-NPS). Tumor growth was measured after 7 days using a digital Vernier caliper. Data is mean ± SEM (n = 6). *p value ≤ 0.05 when compared to respective control. (B) PLGA-CUR NPs represent cyto-compatibility in mice. Following tumor development, the mice were treated intraperitonially with 2.5 mg/kg CUR or equivalent PLGA-CUR NPs or respective vehicle controls. Red blood cells were collected from blood after euthanization under anesthetic condition. Cyto-compatibility of the formulation on red blood cells was evaluated by Olympus BX 41 microscope (Olympus, Center Valley, PA). Bar equals 100 microns.